US 11,896,649 B2
Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
Philippe Valet, Toulouse (FR); Cedric Dray, Toulouse (FR); Vincent Minville, Toulouse (FR); Bernard Frances, Toulouse (FR); Francois Labaste, Toulouse (FR); and Claire Vinel, Toulouse (FR)
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, Toulouse (FR)
Filed by INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, Toulouse (FR)
Filed on Sep. 27, 2022, as Appl. No. 17/935,667.
Application 17/935,667 is a division of application No. 16/077,949, granted, now 11,484,577, previously published as PCT/EP2017/053308, filed on Feb. 14, 2017.
Claims priority of application No. 16305170 (EP), filed on Feb. 15, 2016.
Prior Publication US 2023/0093887 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/22 (2006.01); A61K 31/015 (2006.01); A61P 25/28 (2006.01); A61P 23/00 (2006.01); A61K 31/02 (2006.01); A61K 31/08 (2006.01); A61K 33/00 (2006.01)
CPC A61K 38/22 (2013.01) [A61K 31/015 (2013.01); A61K 31/02 (2013.01); A61K 31/08 (2013.01); A61K 33/00 (2013.01); A61P 23/00 (2018.01); A61P 25/28 (2018.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject at least one dose of a therapeutically effective amount of an APJ receptor agonist, wherein the APJ receptor agonist is apelin-13;
wherein the cognitive impairment is measured prior to and/or following the surgery by performing at least one neuropsychological test to test a function selected from the group consisting of verbal comprehension, perceptual organization, executive function, abstraction, problem solving, cognitive flexibility, visual tracking, game performance, psychomotor performance, psychomotor speed, digital symbol substitution, processing speed, dot-connection, flicker-fusion, simple reaction time, choice reaction time and perceptive accuracy;
wherein the at least one dose of the therapeutically effective amount of the APJ receptor agonist is administered within six hours prior to administration of an anesthetic and/or within six hours following administration of an anesthetic;
wherein the route of administration is selected from the group consisting of oral, implant, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intranasal and rectal; and
wherein the therapeutically effective amount of the APJ receptor agonist is sufficient to reduce or ameliorate the cognitive impairment caused by surgery.